Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing Rivipansel in Sickle Cell Disease and the Published Phase 2 Data.

Ticker(s): GLYC, GBT

Who's the expert?

Name: Dr Julie Kanter - MD

Institution: UAB

  • Associate Professor of Hematology at the University of Alabama at Birmingham and oversees the Adult Sickle Cell Clinic.  
  • Currently manages 1000 - 1100 patients with sickle cell disease.
  • Principal Investigator in a number of large clinical trials related to sickle cell disease and has been involved in the comprehensive care and research for sickle cell disease patients for the past 10 years.

Interview Questions

What per centage of patients with sickle cell disease do you anticipate will be treated with Voxelotor

Added By: doctorlen

How much of a shortening of a VOC hospitalization would be necessary for reviapansel to achieve in order for it to be a commercial success

Added By: doctorlen

What is your guess for pricing of Voxelotor and Rivapansel?

Added By: doctorlen

What would per centage of shortening of an SS crisis would you consider as a success for rivapansel

Added By: doctorlen

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.